Interestingly, patients with high PD-L1 expression were found more likely to have a KRAS mutation, and a subset of patients harboring KRASG12C/TP53 co-mutations was reported to be particularly responsive to pembrolizumab [108, 109], suggesting a potential role of immunotherapy in KRASG12C mutant NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.